We previously reported a patient with synchronous BRAF-mutated metastatic melanoma and BRAF <sup>wt</sup> /KRAS <sup>G12D</sup>-metastatic colorectal cancer (CRC), whose CRC relapsed and progressed when treated with the BRAF inhibitor dabrafenib (GSK2118436). Here, KRAS is linked to colorectal carcinoma.